NCT04146896 - Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN) | Biotech Hunter

Enrollment

228

Participants

Timeline

Start Date

November 12, 2019

Primary Completion Date

February 23, 2022

Study Completion Date

February 23, 2022

Conditions

Diabetic Peripheral Neuropathic Pain

Interventions

DRUG

NYX-2925 50 mg

NYX-2925 administered orally

DRUG

Placebo

Placebo administered orally

Trial Locations (35)

10036

Aptinyx Clinical Site, New York

11235

Aptinyx Clinical Site, Brooklyn

14618

Aptinyx Clinical Site, Rochester

16635

Aptinyx Clinical Site, Duncansville

27103

Aptinyx Clinical Site, Winston-Salem

27834

Aptinyx Clinical Site, Greenville

30030

Aptinyx Clinical Site, Decatur

30060

Aptinyx Clinical Site, Marietta

32789

Aptinyx Clinical Site, Winter Park

33126

Aptinyx Clinical Site, Miami

33144

Aptinyx Clinical Site, Miami

33467

Aptinyx Clinical Site, Greenacres City

33511

Aptinyx Clinical Site, Brandon

33615

Aptinyx Clinical Site, Tampa

33634

Aptinyx Clinical Site, Tampa

33765

Aptinyx Clinical Site, Clearwater

33880

Aptinyx Clinical Site, Winter Haven

34655

Aptinyx Clinical Site, New Port Richey

48307

Aptinyx Clinical Site, Rochester

60422

Aptinyx Clinical Site, Flossmoor

63042

Aptinyx Clinical Site, Hazelwood

75024

Aptinyx Clinical Site, Plano

75149

Aptinyx Clinical Site, Mesquite

77030

Aptinyx Clinical Site, Houston

78229

Aptinyx Clinical Site, San Antonio

83221

Aptinyx Clinical Site, Blackfoot

89123

Aptinyx Clinical Site, Las Vegas

90048

Aptinyx Clinical Site, Los Angeles

90717

Aptinyx Clinical Site, Lomita

91767

Aptinyx Clinical Site, Pomona

92612

Aptinyx Clinical Site, Irvine

92705

Aptinyx Clinical Site, Santa Ana

92780

Aptinyx Clinical Site, Tustin

92860

Aptinyx Clinical Site, Norco

93720

Aptinyx Clinical Site, Fresno